HanchorBio Inc.
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
FiberCop and FMC GlobalSat/MTN Seal Strategic Partnership to Develop Hybrid Terrestrial-satellite Network Architectures in Italy4.11.2025 13:00:00 CET | Press release
The two companies have signed a strategic partnership aimed at offering high-speed connectivity across Italy, enabling high-performance backhaul and last-mile services by integrating satellite backhaul and fiber access in remote areas. ROME, ITALY AND FORT LAUDERDALE, FL / ACCESS Newswire / November 4, 2025 / FiberCop, the company running Italy's most advanced, extensive and widespread digital network infrastructure has signed a strategic partnership with FMC GlobalSat and its 100% owned subsidiary MTNSat "MTN", a world-class satellite network operator, to develop cutting-edge hybrid terrestrial-satellite solutions to deliver stable connectivity in remote areas across Italy. This agreement represents one of the first architectures of its kind developed worldwide over Low Earth Orbit (LEO) satellite networks. Altogether, both companies have successfully completed tests with hybrid network architectures that integrate LEO satellite services into terrestrial infrastructures, specifically
Sauce Labs Introduces Sauce AI for Insights: Purpose-Built AI Agents That Transform Software Quality Data Into Instant Engineering Intelligence3.11.2025 16:00:00 CET | Press release
Purpose-Built AI Agents Eliminate Hours of Manual Test Analysis, Accelerating Release Cycles and Empowering Engineering Teams to Ship High-Quality Applications with Unprecedented Speed and Confidence SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / Sauce Labs, the leading platform for continuous quality, today announced Sauce AI for Insights, a groundbreaking suite of AI-powered data and analytics capabilities that fundamentally transforms how engineering teams analyze, understand, and act on real-time test execution and runtime data to deliver quality releases at speed - while offering enterprise-grade rigorous security and compliance controls. As the industry's first AI agent purpose-built for software quality intelligence, Sauce AI for Insights converts one of the most critical bottlenecks in modern software development into a strategic advantage: the overwhelming volume of test data that slows decision-making and delays releases now accelerates developer productivity and en
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S3.11.2025 16:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / November 3, 2025 / Pacific Avenue Capital Partners ("Pacific Avenue"), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced it has completed the acquisition of FLSmidth Cement A/S ("FLSmidth Cement" or "Company"), from FLSmidth & Co. A/S (CPH:FLS) ("FLSmidth"). With the completion of the transaction, FLSmidth Cement will operate under the new name Fuller Technologies ("Fuller"), marking the beginning of its next chapter as an independent, technology-driven leader serving the global cement sector. Fuller is a leading solutions provider for the cement production industry focused on providing aftermarket parts and services to as well as new and replacement equipment for cement plants around the globe. The Company has manufacturing locations in North America, Europe, and Asia, and its global installed base spans over 1,400 of the world's approximate 2,700 cement plants. Wi
Scam Encounters Every Four Days: Mexico's Financial Toll3.11.2025 13:00:00 CET | Press release
This study of 1,000 Mexican adults reveals that over three-quarters have encountered a scam, with an average of one scam encounter happening every four days, equating to 86 scam encounters on average per person per year in Mexico. THE HAGUE, NL / ACCESS Newswire / November 3, 2025 / Additionally, nearly 3/5 of Mexican adults claim to have experienced a scam in the last year, with each scam victim being scammed on average 1.8 times. With widespread financial losses Shopping scams (55%), investment scams (48%) and unexpected money scams (47%) are the most common types of scams in Mexico, with some having money stolen via email while others received kidnapping threats. Additionally, over 1/3 of Mexican adults claim to have lost money to scams in the last year. Wire or bank transfers (55%) and debitcard payments (21%) are the most common methods used by scammers to receive payment. Of those who have experienced being scammed, 2/3 have reported the scam to the payment service, and half of t
Market Logic Software and Euromonitor International Announce New Data Integration: DeepSights(TM) to Enhance AI-Driven Insights for Customers3.11.2025 10:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / November 3, 2025 / Market Logic Software, a leading provider of insights management solutions, is proud to announce a strategic integration with Euromonitor International, a global data analytics company. This collaboration will enable shared customers to seamlessly access Euromonitor's unparalleled market intelligence through Market Logic's AI for insights, platform, DeepSightsTM. The integration will provide a comprehensive streamlined experience for enterprises seeking growth. Market Logic has more than a decade's experience delivering solutions that allow businesses to centralize and leverage their consumer and market insights effectively. By integrating Euromonitor's extensive market research and intelligence content directly into DeepSights, shared clients will now benefit from a more unified and efficient insights management experience, powered by AI. "We are excited to be deepening our ongoing partnership with Euromonitor," said Olaf Lenzmann, Chi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom